Roche (OTCMKTS:RHHBY) Reaches New 52-Week High – Here’s What Happened

Posted by Francis Steltz on Nov 9th, 2026

Shares of Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) reached a new 52-week high on Monday. The stock traded as high as $61.51 and last traded at $61.51, with a volume of 503,200 shares. The stock had previously closed at $59.37.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on RHHBY. Morgan Stanley upgraded Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 price target for the company in a report on Friday, August 7th. Royal Bank Of Canada initiated coverage on Roche in a report on Tuesday, September 8th. They set an “outperform” rating on the stock. HSBC reiterated a “hold” rating on shares of Roche in a report on Thursday, September 10th. Zacks Research upgraded Roche from a “strong sell” rating to a “hold” rating in a research report on Monday, August 24th. Finally, Deutsche Bank Aktiengesellschaft raised Roche from a “hold” rating to a “buy” rating in a research note on Friday, October 23rd. Eight investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Roche presently has a consensus rating of “Moderate Buy” and an average price target of $60.00.

View Our Latest Research Report on RHHBY

Roche Trading Up 4.0%

The company has a current ratio of 1.23, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. The business’s fifty day moving average is $55.86 and its 200 day moving average is $53.88.

Institutional Trading of Roche

Several hedge funds and other institutional investors have recently modified their holdings of the company. Confluence Investment Management LLC raised its stake in shares of Roche by 1.2% in the 2nd quarter. Confluence Investment Management LLC now owns 20,925 shares of the company’s stock valued at $1,074,000 after purchasing an additional 258 shares during the period. Enterprise Financial Services Corp boosted its position in shares of Roche by 6.6% during the first quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company’s stock worth $277,000 after buying an additional 345 shares during the period. Archer Investment Corp grew its holdings in shares of Roche by 7.7% during the first quarter. Archer Investment Corp now owns 5,598 shares of the company’s stock worth $278,000 after buying an additional 398 shares in the last quarter. Fulton Bank N.A. grew its holdings in shares of Roche by 5.1% during the second quarter. Fulton Bank N.A. now owns 11,572 shares of the company’s stock worth $597,000 after buying an additional 559 shares in the last quarter. Finally, McIlrath & Eck LLC bought a new position in shares of Roche during the first quarter worth about $39,000.

Roche Company Profile

(Get Free Report)

Roche is a Swiss healthcare company with two main businesses: pharmaceuticals and diagnostics. Founded in Basel in 1896, the company develops and commercializes medicines and provides diagnostic tests, instruments, and digital health solutions.

Its pharmaceutical research and products span areas including oncology, immunology, neuroscience, ophthalmology, and infectious diseases. Its diagnostics business serves clinical laboratories, hospitals, healthcare providers, and patients with tools used to detect and monitor a range of medical conditions.

Headquartered in Basel, Roche operates in markets around the world.